Literature DB >> 8815564

Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome.

S Gando1, T Kameue, S Nanzaki, Y Nakanishi.   

Abstract

To evaluate the role of disseminated intravascular coagulation (DIC) and to determine the influence of antithrombin, protein C, and plasminogen activator inhibitor 1 on multiple organ dysfunction syndrome (MODS) and outcome in patients with systemic inflammatory response syndrome (SIRS), we made a prospective cohort study. The study subjects consisted of thirty-five patients who exhibited two or more of the conditions of SIRS for more than three consecutive days. They were classified into subgroups of survivors (n = 13) and nonsurvivors (n = 22). The global coagulation and fibrinolytic markers, antithrombin, protein C, and plasminogen activator inhibitor 1 were measured on the day of the diagnosis of SIRS, and also on the 1st, 3rd, and 5th days. The results of these measurements, demographic data, criteria of severity, incidence of MODS were compared between the subgroups. For prediction of patient's death, a receiver operating characteristic (ROC) curve analysis was made. DIC was frequently associated with SIRS patients (29/35, 82.9%). A significant decrease in the DIC score was found in the survivors (p = 0.0001). None of them suffered from DIC on the 5th day. In the nonsurvivors, low levels of protein C and antithrombin and markedly high values of plasminogen activator inhibitor 1 continued up to the 5th day, no improvement of the DIC was observed during the study period and the number of the dysfunctioning organs were significantly higher than in the survivors. Plasminogen activator inhibitor 1 on the 5th day had prognostic value for the prediction of death on the SIRS patients. In conclusion, DIC occurs commonly in patients with SIRS and may be the main determinant for the outcome of these patients. Changes in antithrombin, protein C, and plasminogen activator inhibitor 1 are one of the aggravating factors of MODS. Furthermore, plasminogen activator inhibitor 1 is a good predictor of death in these patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815564

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  33 in total

Review 1.  Disseminated intravascular coagulation: old disease, new hope.

Authors:  Cheng Hock Toh; Michael Dennis
Journal:  BMJ       Date:  2003-10-25

2.  Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

Review 3.  The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.

Authors:  Karen M Hook; Charles S Abrams
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

4.  Blood Components Load in Post-operative Neurosurgical Patients Suspected with Disseminated Intravascular Coagulation.

Authors:  M Kotru; S S Munjal; M Singh; T Seth; H P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-09       Impact factor: 0.900

5.  Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.

Authors:  Ines J Laudes; Jeffrey C Chu; Sujata Sikranth; Markus Huber-Lang; Ren-Feng Guo; Niels Riedemann; J Vidya Sarma; Alvin H Schmaier; Peter A Ward
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

6.  Modified score for disseminated intravascular coagulation in the critically ill.

Authors:  Mirka Sivula; Minna Tallgren; Ville Pettilä
Journal:  Intensive Care Med       Date:  2005-06-15       Impact factor: 17.440

7.  Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation.

Authors:  Seiji Madoiwa; Shin Nunomiya; Tomoko Ono; Yuichi Shintani; Tsukasa Ohmori; Jun Mimuro; Yoichi Sakata
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

Review 8.  Antithrombin in the treatment of burn trauma.

Authors:  Areta Kowal-Vern; Bruce A Orkin
Journal:  World J Crit Care Med       Date:  2016-02-04

9.  A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments.

Authors:  Ann R Kennedy; Amit Maity; Jenine K Sanzari
Journal:  Radiat Res       Date:  2016-07-26       Impact factor: 2.841

10.  Prothrombotic and Proinflammatory Activities of the β-Hemolytic Group B Streptococcal Pigment.

Authors:  Nikolai Siemens; Sonja Oehmcke-Hecht; Jörn Hoßmann; Sebastian B Skorka; Roel H T Nijhuis; Corinne Ruppen; Steinar Skrede; Manfred Rohde; Daniel Schultz; Michael Lalk; Andreas Itzek; Dietmar H Pieper; Christiaan J van den Bout; Eric C J Claas; Ed J Kuijper; Robert Mauritz; Parham Sendi; Herman F Wunderink; Anna Norrby-Teglund
Journal:  J Innate Immun       Date:  2019-11-19       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.